Log in
NASDAQ:BIB

ProShares Ultra Nasdaq Biotechnology Stock Forecast, Price & News

$77.35
+4.43 (+6.08 %)
(As of 11/27/2020 12:00 AM ET)
Add
Today's Range
$73.94
Now: $77.35
$77.44
50-Day Range
$64.59
MA: $72.30
$79.22
52-Week Range
$35.49
Now: $77.35
$83.06
Volume121,052 shs
Average Volume204,337 shs
Market Capitalization$197.24 million
P/E RatioN/A
Dividend Yield0.00%
BetaN/A
ProShares Ultra Nasdaq Biotechnology (the Fund) seeks daily investment results, before fees and expenses, that correspond to twice (200%) the daily performance of the Index. The return of the Fund for a period longer than a single trading day will be the result of each day's returns compounded over the period, which will very likely differ from the inverse of the return of the Dow Jones United States Basic Materials Index (the Index) for that period. The Fund does not seek to achieve its stated investment objective over a period of time greater than one day. The Fund invests in derivatives that have similar daily performance characteristics as the inverse of the daily return of the Index. The Fund invests in financial instruments whose value is derived from the value of an underlying asset, interest rate or index. ProShare Advisors LLC is the investment advisor of the Fund.
Read More

Geographic Exposure of BIB

Currency Exposure of BIB

Sector Exposure of BIB

Industry Exposure of BIB

Basic Details

Issuer ProShares
Fund NameProShares Ultra Nasdaq Biotechnology
Tax ClassificationRegulated Investment Company
SymbolNASDAQ:BIB
Inception Date4/6/2010
Fund ManagerMichael Neches, Tarak Dave
Phone+1-240-4976400

Fund Focus

Asset ClassEquity
BenchmarkNasdaq Biotech Index
CategorySector
FocusHealth Care
Development LevelDeveloped Markets
RegionNorth America

Fund Statistics

Assets Under Management$193.76 million
Average Daily Volume$162,193.00
Discount/Premium-0.09%

ETF Expenses

Management Fee0.75%
Other Expenses0.29%
Total Expenses1.04%
Fee Waiver-0.09%
Net Expenses0.95%

Administrator, Advisor and Custodian

AdministratorJ.P. Morgan Investor Services Co.
AdvisorProShare Advisors LLC
CustodianJPMorgan Chase Bank, N.A.
DistributorSEI Investments Distribution Co.
Transfer AgentJPMorgan Chase Bank, N.A.
Trustee
Lead Market MakerVirtu Financial
$77.35
+4.43 (+6.08 %)
(As of 11/27/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive BIB News and Ratings via Email

Sign-up to receive the latest news and ratings for BIB and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB) Frequently Asked Questions

How has ProShares Ultra Nasdaq Biotechnology's stock been impacted by COVID-19 (Coronavirus)?

ProShares Ultra Nasdaq Biotechnology's stock was trading at $47.23 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, BIB stock has increased by 63.8% and is now trading at $77.35.
View which stocks have been most impacted by COVID-19
.

What stocks does MarketBeat like better than ProShares Ultra Nasdaq Biotechnology?

Wall Street analysts have given ProShares Ultra Nasdaq Biotechnology a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but ProShares Ultra Nasdaq Biotechnology wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What other stocks do shareholders of ProShares Ultra Nasdaq Biotechnology own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ProShares Ultra Nasdaq Biotechnology investors own include The Walt Disney (DIS), Gilead Sciences (GILD), Micron Technology (MU), NVIDIA (NVDA), Starbucks (SBUX), Advanced Micro Devices (amd), Alibaba Group (BABA), Pfizer (PFE), Intel (INTC) and Visa (V).

What is ProShares Ultra Nasdaq Biotechnology's stock symbol?

ProShares Ultra Nasdaq Biotechnology trades on the NASDAQ under the ticker symbol "BIB."

Who are ProShares Ultra Nasdaq Biotechnology's major shareholders?

ProShares Ultra Nasdaq Biotechnology's stock is owned by a variety of institutional and retail investors. Top institutional investors include Toth Financial Advisory Corp (0.74%), Capital Investment Advisors LLC (0.47%), Bank Julius Baer & Co. Ltd Zurich (0.20%) and Morgan Stanley (0.07%).

Which institutional investors are selling ProShares Ultra Nasdaq Biotechnology stock?

BIB stock was sold by a variety of institutional investors in the last quarter, including Bank Julius Baer & Co. Ltd Zurich, Toth Financial Advisory Corp, and Morgan Stanley.

Which institutional investors are buying ProShares Ultra Nasdaq Biotechnology stock?

BIB stock was acquired by a variety of institutional investors in the last quarter, including Capital Investment Advisors LLC.

How do I buy shares of ProShares Ultra Nasdaq Biotechnology?

Shares of BIB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is ProShares Ultra Nasdaq Biotechnology's stock price today?

One share of BIB stock can currently be purchased for approximately $77.35.

How big of a company is ProShares Ultra Nasdaq Biotechnology?

ProShares Ultra Nasdaq Biotechnology has a market capitalization of $197.24 million.

What is ProShares Ultra Nasdaq Biotechnology's official website?

The official website for ProShares Ultra Nasdaq Biotechnology is www.proshares.com.

How can I contact ProShares Ultra Nasdaq Biotechnology?

ProShares Ultra Nasdaq Biotechnology's mailing address is SUITE 1000, 7501 WISCONSIN AVENUE, BETHESDA, MD 20814, United States. The exchange traded fund can be reached via phone at +1-240-4976400.

This page was last updated on 11/28/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.